Sutent approved in Canada
Posted by Julie Royster (jroyster) on Jun 01 2006
GIST In the News >>

Pfizer Canada announced May 31, 2006 that its oral multi-targeted agent, SUTENT (sunitinib malate) has been approved by Health Canada for the treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to intolerance or resistance.  Link here for the full news story.

Last changed: Jun 01 2006 at 8:27 AM

Back